You searched for biotime - Page 2 of 3

Early, but encouraging data from Asterias on stem cells for spinal cord injury

September 14, 2016 February 1, 2021 / By Professor Paul Knoepfler, Ph.D.

As I posted recently, Asterias Biotherapeutics has had good early safety results so far in its historic stem cell trial for spinal cord injury and now the company presented some early, encouraging hints at efficacy. However, a caveat here is that this is not an RCT (randomized controlled trial). Ed Wirth, CMO of Asterias, presented the …

Early, but encouraging data from Asterias on stem cells for spinal cord injury Read More »

Stem cell good news briefs: TiGenix, Asterias, CIRM, Awards, & More

September 1, 2015 December 22, 2023 / By Professor Paul Knoepfler, Ph.D. / 4 Comments

There’s a growing stream of stem cell good news of late. Stem cell biotech, TiGenix, reported encouraging Phase 3 allogeneic results on stem cells. A big milestone. I can’t wait to see the actual data. Its product, Cx601, has so far been safe and effective for perianal fistulas in Crohn’s disease. See more from Alexey on this. CIRM has funded the largest …

Stem cell good news briefs: TiGenix, Asterias, CIRM, Awards, & More Read More »

Michael Cea ISSCR chat with Jeanne Loring on stem cell field

August 5, 2015 December 22, 2023 / By Professor Paul Knoepfler, Ph.D. / 3 Comments

ISSCR Chat By Michael Cea Jeanne Loring of the Scripps Research Institute in La Jolla, California kindly sat down with me at the ISSCR annual meeting for a broad discussion of her history, views on the field and developments in the science. I found Jeanne a refreshing character, as I did a number of others I was …

Michael Cea ISSCR chat with Jeanne Loring on stem cell field Read More »

Tale of 7 stem cell biotech stock woes

July 23, 2015 February 1, 2021 / By Professor Paul Knoepfler, Ph.D. / 11 Comments

To get from point A of a stem cell discovery to point B of a patient actually receiving a treatment based on that discovery is a long and non-linear road, which requires biotech company research. Stem cell biotech companies including publicly traded companies are an integral part of the field making that journey. How those …

Tale of 7 stem cell biotech stock woes Read More »

Rensselaer Polytechnic Institute stem cell meeting report

June 16, 2015 February 1, 2021 / By Professor Paul Knoepfler, Ph.D. / 1 Comment

Last week I attended and spoke at a stem cell meeting at Rensselaer Polytechnic Institute (RPI). It was entitled, “Bioengineering and Stem Cell Research”. It was a great meeting with many interesting talks. Below I write about some of the talks and themes of the meeting. Still to come later this week I will do a second post entirely …

Rensselaer Polytechnic Institute stem cell meeting report Read More »

Positive Stem Cell Developments in 2014

December 24, 2014 December 22, 2023 / By Professor Paul Knoepfler, Ph.D. / 2 Comments

A lot has happened in 2014 in the stem cell and regenerative medicine field and so much of it has been good news so let’s focus on the positive. These positive developments are often the result of many years of creative, hard work by amazing teams of researchers. Here is my top 10 list of …

Positive Stem Cell Developments in 2014 Read More »

Stem Cell Person of the Year Award 2014 Voting: Who Will Be Finalists?

October 15, 2014 December 22, 2023 / By Professor Paul Knoepfler, Ph.D.

With one week left to vote to pick the top 12 finalists for the Stem Cell Person of the Year 2014 Award, we have more than 2,800 votes in so far. From the top 12 vote-getters, I will choose the winner. This is the third year of this award. I self-fund this award out of …

Stem Cell Person of the Year Award 2014 Voting: Who Will Be Finalists? Read More »

Advanced Cell Technology pub: Trial for Macular Degeneration

October 14, 2014 February 1, 2021 / By Professor Paul Knoepfler, Ph.D. / 8 Comments

The stem cell biotech Advanced Cell Technology (ACT) reported new, positive data in a paper in Lancet from their clinical trials using retinal pigmented epithelial cells (RPEs) made from human embryonic stem cells (hESC) for treatment of different forms of macular degeneration (MD). The paper was entitled “Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related …

Advanced Cell Technology pub: Trial for Macular Degeneration Read More »

Stem Cell Person of the Year 2014 Award: Vote To Choose 12 Finalists

October 8, 2014 December 22, 2023 / By Professor Paul Knoepfler, Ph.D. / 4 Comments

Nominations have closed and we have more than two dozen nominations for Stem Cell Person of the Year 2014. It’s an exciting, diverse group including some news faces as well as nominees from years past as well. Happy Stem Cell Day! You can now vote for your choice for the top finalists in the poll …

Stem Cell Person of the Year 2014 Award: Vote To Choose 12 Finalists Read More »

Interview with Jane Lebkowski on Asterias FDA-approved Stem Cell Trial

August 28, 2014 February 1, 2021 / By Professor Paul Knoepfler, Ph.D. / 1 Comment

The BioTime subsidiary, Asterias, has received FDA approval for a combined Phase I/IIa clinical trial of OPC1 for treating spinal cord injury. BioTime (BTX) and Asterias (ASTY) have picked up the portfolio of the former Geron clinical trial using oligodendrocyte precursor cells (OPC). Asterias also acquired a second element from Geron in the form of a lung …

Interview with Jane Lebkowski on Asterias FDA-approved Stem Cell Trial Read More »

Search Results for: biotime